NorthCrest Asset Manangement’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $808K | Buy |
6,262
+469
| +8% | +$60.6K | 0.02% | 339 |
|
|
2025
Q1 | $641K | Sell |
5,793
-850
| -13% | -$94K | 0.02% | 380 |
|
|
2024
Q4 | $907K | Buy |
6,643
+1,493
| +29% | +$204K | 0.03% | 309 |
|
|
2024
Q3 | $593K | Buy |
5,150
+10
| +0.2% | +$1.15K | 0.02% | 378 |
|
|
2024
Q2 | $708K | Buy |
5,140
+19
| +0.4% | +$2.62K | 0.02% | 321 |
|
|
2024
Q1 | $706K | Sell |
5,121
-270
| -5% | -$37.2K | 0.02% | 322 |
|
|
2023
Q4 | $710K | Hold |
5,391
| – | – | 0.03% | 315 |
|
|
2023
Q3 | $606K | Hold |
5,391
| – | – | 0.02% | 330 |
|
|
2023
Q2 | $508K | Hold |
5,391
| – | – | 0.02% | 352 |
|
|
2023
Q1 | $546K | Buy |
5,391
+41
| +0.8% | +$4.15K | 0.02% | 348 |
|
|
2022
Q4 | $639K | Hold |
5,350
| – | – | 0.04% | 241 |
|
|
2022
Q3 | $568K | Hold |
5,350
| – | – | 0.03% | 283 |
|
|
2022
Q2 | $522K | Hold |
5,350
| – | – | 0.03% | 300 |
|
|
2022
Q1 | $502K | Buy |
+5,350
| New | +$502K | 0.02% | 300 |
|